October 09, 2020
2 min watch
Save
VIDEO: Combinations with EGFR inhibitors emerge for treating mNSCLC
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Jyoti D. Patel, MD, associate vice chair for clinical research and professor of medicine at Northwestern’s Feinberg School of Medicine, discussed two presentations from the ESMO Virtual Congress 2020.
The first-line option for patients with advanced EGFR-mutated non-small cell lung cancer is currently osimertinib (Tagrisso; AstraZeneca). However, “there are efforts to improve outcomes,” Patel said.
The studies presented focused on anti-VEGF combined with osimertinib as well as another targeting HER-3 expression.
References:
- Yu H, et al. Abstract LBA62. Presented at: European Society for Medical Oncology Virtual Congress 2020; Sept. 19-21, 2020.
- Yukihiro T, et al. Abstract 1259O. Presented at: European Society for Medical Oncology Virtual Congress 2020; Sept. 19-21, 2020.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Patel reports serving as a consultant for Astra Zeneca, AbbVie, Genentech and Takeda, and receiving research funding to her institution from Bristol-Meyer Squibb.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.